Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 53 entries
Sorted by: Best Match Show Resources per page
Fumes from the spleen.

Paediatric and perinatal epidemiology

[No authors listed]
PMID: 2587404
Paediatr Perinat Epidemiol. 1989 Oct;3(4):353-5.

No abstract available.

Cite
Fumes from the spleen. Paediatr Perinat Epidemiol. 1989;3(4):353-5
(1989). Fumes from the spleen. Paediatric and perinatal epidemiology, 3(4), 353-5.
"Fumes from the spleen." Paediatric and perinatal epidemiology vol. 3,4 (1989): 353-5.
Fumes from the spleen. Paediatr Perinat Epidemiol. 1989 Oct;3(4):353-5. PMID: 2587404.
Copy Download .nbib Format: NLM
Clinical research in general medical journals.

The New England journal of medicine

Krantz KD.
PMID: 503146
N Engl J Med. 1979 Dec 06;301(23):1292-3.

No abstract available.

Cite
Krantz KD. Clinical research in general medical journals. N Engl J Med. 1979;301(23):1292-3
Krantz, K. D. (1979). Clinical research in general medical journals. The New England journal of medicine, 301(23), 1292-3.
Krantz, K D. "Clinical research in general medical journals." The New England journal of medicine vol. 301,23 (1979): 1292-3.
Krantz KD. Clinical research in general medical journals. N Engl J Med. 1979 Dec 06;301(23):1292-3. PMID: 503146.
Copy Download .nbib Format: NLM
The state of outcome research: are we on target?.

The New England journal of medicine

Greenfield S.
PMID: 2710176
N Engl J Med. 1989 Apr 27;320(17):1142-3. doi: 10.1056/NEJM198904273201710.

No abstract available.

Cite
Greenfield S. The state of outcome research: are we on target?. N Engl J Med. 1989;320(17):1142-3doi: 10.1056/NEJM198904273201710.
Greenfield, S. (1989). The state of outcome research: are we on target?. The New England journal of medicine, 320(17), 1142-3. https://doi.org/10.1056/NEJM198904273201710
Greenfield, S. "The state of outcome research: are we on target?." The New England journal of medicine vol. 320,17 (1989): 1142-3. doi: https://doi.org/10.1056/NEJM198904273201710
Greenfield S. The state of outcome research: are we on target?. N Engl J Med. 1989 Apr 27;320(17):1142-3. doi: 10.1056/NEJM198904273201710. PMID: 2710176.
Copy Download .nbib Format: NLM
National Cancer Institute-supported clinical trials networks.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Abrams J, Kramer B, Doroshow JH, Varmus H.
PMID: 25452448
J Clin Oncol. 2015 Jan 20;33(3):293. doi: 10.1200/JCO.2014.59.5421. Epub 2014 Dec 01.

No abstract available.

Cite
Abrams J, Kramer B, Doroshow JH, et al. National Cancer Institute-supported clinical trials networks. J Clin Oncol. 2014;33(3):293doi: 10.1200/JCO.2014.59.5421.
Abrams, J., Kramer, B., Doroshow, J. H., & Varmus, H. (2015). National Cancer Institute-supported clinical trials networks. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 33(3), 293. https://doi.org/10.1200/JCO.2014.59.5421
Abrams, Jeffrey, et al. "National Cancer Institute-supported clinical trials networks." Journal of clinical oncology : official journal of the American Society of Clinical Oncology vol. 33,3 (2015): 293. doi: https://doi.org/10.1200/JCO.2014.59.5421
Abrams J, Kramer B, Doroshow JH, Varmus H. National Cancer Institute-supported clinical trials networks. J Clin Oncol. 2015 Jan 20;33(3):293. doi: 10.1200/JCO.2014.59.5421. Epub 2014 Dec 01. PMID: 25452448.
Copy Download .nbib Format: NLM
Industry, FDA warm to "adaptive" trials.

JAMA

Kuehn BM.
PMID: 17062852
JAMA. 2006 Oct 25;296(16):1955-7. doi: 10.1001/jama.296.16.1955.

No abstract available.

Cite
Kuehn BM. Industry, FDA warm to "adaptive" trials. JAMA. 2006;296(16):1955-7doi: 10.1001/jama.296.16.1955.
Kuehn, B. M. (2006). Industry, FDA warm to "adaptive" trials. JAMA, 296(16), 1955-7. https://doi.org/10.1001/jama.296.16.1955
Kuehn, Bridget M. "Industry, FDA warm to "adaptive" trials." JAMA vol. 296,16 (2006): 1955-7. doi: https://doi.org/10.1001/jama.296.16.1955
Kuehn BM. Industry, FDA warm to "adaptive" trials. JAMA. 2006 Oct 25;296(16):1955-7. doi: 10.1001/jama.296.16.1955. PMID: 17062852.
Copy Download .nbib Format: NLM
Pharmaceutical futures: made in China?.

Nature

Cyranoski D.
PMID: 18971994
Nature. 2008 Oct 30;455(7217):1168-70. doi: 10.1038/4551168a.

No abstract available.

Cite
Cyranoski D. Pharmaceutical futures: made in China?. Nature. 2008;455(7217):1168-70doi: 10.1038/4551168a.
Cyranoski, D. (2008). Pharmaceutical futures: made in China?. Nature, 455(7217), 1168-70. https://doi.org/10.1038/4551168a
Cyranoski, David. "Pharmaceutical futures: made in China?." Nature vol. 455,7217 (2008): 1168-70. doi: https://doi.org/10.1038/4551168a
Cyranoski D. Pharmaceutical futures: made in China?. Nature. 2008 Oct 30;455(7217):1168-70. doi: 10.1038/4551168a. PMID: 18971994.
Copy Download .nbib Format: NLM
An audience with... Jan M. Lundberg.

Nature reviews. Drug discovery

Lundberg JM.
PMID: 15959949
Nat Rev Drug Discov. 2005 Jun;4(6):452. doi: 10.1038/nrd1764.

No abstract available.

Cite
Lundberg JM. An audience with... Jan M. Lundberg. Nat Rev Drug Discov. 2005;4(6):452doi: 10.1038/nrd1764.
Lundberg, J. M. (2005). An audience with... Jan M. Lundberg. Nature reviews. Drug discovery, 4(6), 452. https://doi.org/10.1038/nrd1764
Lundberg, Jan M. "An audience with... Jan M. Lundberg." Nature reviews. Drug discovery vol. 4,6 (2005): 452. doi: https://doi.org/10.1038/nrd1764
Lundberg JM. An audience with... Jan M. Lundberg. Nat Rev Drug Discov. 2005 Jun;4(6):452. doi: 10.1038/nrd1764. PMID: 15959949.
Copy Download .nbib Format: NLM
[Characteristics of childhood tuberculosis].

Pneumologie (Stuttgart, Germany)

Detjen AK, Magdorf K.
PMID: 19259916
Pneumologie. 2009 Apr;63(4):207-18. doi: 10.1055/s-0028-1100827. Epub 2009 Mar 03.

In spite of a decline in the western industrialised countries, tuberculosis remains one of the commonest causes of childhood mortality in the world. In most cases, children become infected by adults in their immediate environment. The clinical manifestation as...

Cite
Detjen AK, Magdorf K. Besonderheiten der Kindertuberkulose. [Characteristics of childhood tuberculosis]. Pneumologie. 2009;63(4):207-18doi: 10.1055/s-0028-1100827.
Detjen, A. K., & Magdorf, K. (2009). Besonderheiten der Kindertuberkulose. [Characteristics of childhood tuberculosis]. Pneumologie (Stuttgart, Germany), 63(4), 207-18. https://doi.org/10.1055/s-0028-1100827
Detjen, A K, and Magdorf, K. "Besonderheiten der Kindertuberkulose." [Characteristics of childhood tuberculosis]. Pneumologie (Stuttgart, Germany) vol. 63,4 (2009): 207-18. doi: https://doi.org/10.1055/s-0028-1100827
Detjen AK, Magdorf K. Besonderheiten der Kindertuberkulose. [Characteristics of childhood tuberculosis]. Pneumologie. 2009 Apr;63(4):207-18. doi: 10.1055/s-0028-1100827. Epub 2009 Mar 03. German. PMID: 19259916.
Copy Download .nbib Format: NLM
[Evidence and eminence].

Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG

Rzany B.
PMID: 19138283
J Dtsch Dermatol Ges. 2008 Dec;6:S1-2. doi: 10.1111/j.1610-0387.2008.06956.x.

No abstract available.

Cite
Rzany B. Evidenz und eminenz. [Evidence and eminence]. J Dtsch Dermatol Ges. 2008;6:S1-2doi: 10.1111/j.1610-0387.2008.06956.x.
Rzany, B. (2008). Evidenz und eminenz. [Evidence and eminence]. Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG, 6S1-2. https://doi.org/10.1111/j.1610-0387.2008.06956.x
Rzany, Berthold. "Evidenz und eminenz." [Evidence and eminence]. Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG vol. 6 (2008): S1-2. doi: https://doi.org/10.1111/j.1610-0387.2008.06956.x
Rzany B. Evidenz und eminenz. [Evidence and eminence]. J Dtsch Dermatol Ges. 2008 Dec;6:S1-2. doi: 10.1111/j.1610-0387.2008.06956.x. German. PMID: 19138283.
Copy Download .nbib Format: NLM
Innovative drug R&D in China.

Nature reviews. Drug discovery

Qi J, Wang Q, Yu Z, Chen X, Wang F.
PMID: 21532556
Nat Rev Drug Discov. 2011 May;10(5):333-4. doi: 10.1038/nrd3435.

No abstract available.

Cite
Qi J, Wang Q, Yu Z, et al. Innovative drug R&D in China. Nat Rev Drug Discov. 2011;10(5):333-4doi: 10.1038/nrd3435.
Qi, J., Wang, Q., Yu, Z., Chen, X., & Wang, F. (2011). Innovative drug R&D in China. Nature reviews. Drug discovery, 10(5), 333-4. https://doi.org/10.1038/nrd3435
Qi, Jingzong, et al. "Innovative drug R&D in China." Nature reviews. Drug discovery vol. 10,5 (2011): 333-4. doi: https://doi.org/10.1038/nrd3435
Qi J, Wang Q, Yu Z, Chen X, Wang F. Innovative drug R&D in China. Nat Rev Drug Discov. 2011 May;10(5):333-4. doi: 10.1038/nrd3435. PMID: 21532556.
Copy Download .nbib Format: NLM
Publicly funded clinical trials and the future of cancer care.

The oncologist

Schilsky RL.
PMID: 23363807
Oncologist. 2013;18(2):232-8. doi: 10.1634/theoncologist.2012-0423. Epub 2013 Jan 30.

Publicly sponsored trials, conducted primarily by cooperative groups sponsored by the National Cancer Institute, and commercially sponsored trials are necessary to create new knowledge, improve the care of oncology patients, and develop new drugs and devices. Commercial sponsors launch...

Cite
Schilsky RL. Publicly funded clinical trials and the future of cancer care. Oncologist. 2013;18(2):232-8doi: 10.1634/theoncologist.2012-0423.
Schilsky, R. L. (2013). Publicly funded clinical trials and the future of cancer care. The oncologist, 18(2), 232-8. https://doi.org/10.1634/theoncologist.2012-0423
Schilsky, Richard L. "Publicly funded clinical trials and the future of cancer care." The oncologist vol. 18,2 (2013): 232-8. doi: https://doi.org/10.1634/theoncologist.2012-0423
Schilsky RL. Publicly funded clinical trials and the future of cancer care. Oncologist. 2013;18(2):232-8. doi: 10.1634/theoncologist.2012-0423. Epub 2013 Jan 30. PMID: 23363807; PMCID: PMC3579608.
Copy Download .nbib Format: NLM
Tools & Techniques - statistics: non-inferiority trials.

EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology

Collier TJ.
PMID: 25138191
EuroIntervention. 2014 Aug;10(4):526-7. doi: 10.4244/EIJV10I4A90.

No abstract available.

Cite
Collier TJ. Tools & Techniques - statistics: non-inferiority trials. EuroIntervention. 2014;10(4):526-7doi: 10.4244/EIJV10I4A90.
Collier, T. J. (2014). Tools & Techniques - statistics: non-inferiority trials. EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology, 10(4), 526-7. https://doi.org/10.4244/EIJV10I4A90
Collier, Timothy John. "Tools & Techniques - statistics: non-inferiority trials." EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology vol. 10,4 (2014): 526-7. doi: https://doi.org/10.4244/EIJV10I4A90
Collier TJ. Tools & Techniques - statistics: non-inferiority trials. EuroIntervention. 2014 Aug;10(4):526-7. doi: 10.4244/EIJV10I4A90. PMID: 25138191.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 53 entries